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Introduction
============

Chronic inflammation is an important risk factor for cardiovascular disease (CVD)^[@bib1]--[@bib5])^. Chronic inflammatory diseases, such as systemic lupus erythematosus^[@bib6])^, rheumatoid arthritis^[@bib7])^, psoriatic arthritis^[@bib8])^, and inflammatory bowel disease^[@bib9],\ [@bib10])^, may be associated with an increased risk of CVD.

Eczema, which is also a chronic inflammatory disorder, appears to affect adults as well as children^[@bib11]--[@bib13])^. Some studies associate eczema with CVD risk, probably through inflammation^[@bib14],\ [@bib15])^. However, several studies have reported null findings about eczema and CVD^[@bib16],\ [@bib17])^, so the association is still controversial. In addition, existing reports using population-based cohort studies are mainly from Western countries; no Japanese cohort study has investigated the association between eczema and risk of CVD.

Therefore, we aimed to prospectively examine the association of eczema with mortality from several major CVDs, including CHD, heart failure, stroke and aortic aneurysm, using a Japanese population-based cohort study. Furthermore, we examined whether the effect is modified by age or sex.

Methods
=======

Study Population
----------------

The Japan Collaborative Cohort (JACC) Study for Evaluation of Cancer Risks, sponsored by the Ministry of Education, Sport, and Science, conducted a baseline survey from 1988 to 1990 in 45 areas throughout Japan. Details of this survey have been described elsewhere^[@bib18])^. Briefly, participants completed self-administered questionnaires about their lifestyles and medical histories, including previous CVD, cancer, and other diseases at baseline. The ethics committees of the Nagoya University School of Medicine and the Osaka University Graduate School of Medicine approved the study.

Of a total of 110,585 individuals, aged 40 to 79 years, 90,035 participants answered the question about their skin status. We further excluded participants who had any previous history of CHD, stroke or cancer at baseline. Consequently, 85,099 participants (35,489 men and 49,610 women) were included in this study.

Main Exposure: Self-Reported Frequency of Eczema
------------------------------------------------

We asked participants about the frequency eczema appearance. Participants were requested to choose their answer to this question from the following three categories: "Often," "Sometimes," or "Seldom."

Other Cardiovascular Risk Factors
---------------------------------

We selected a number of CVD risk factors, including age, sex, body mass index (sex-specific quintiles), history of hypertension, history of diabetes, smoking status (never, ex-smoker, or current smokers of 1 to 19 or ≥ 20 cigarettes per day), alcohol intake categories (never, ex-drinker, or current drinkers of ethanol at 1 to 22, 23 to 45, 46 to 68, or ≥ 69g per day), hours of walking (never, 1 to 2, 3 to 4, or ≥ 5 hours per week), sport participation (never, 1 to 2, 3 to 4, or ≥ 5 hours per week), perceived mental stress (low, medium, or high), hours of sleep (≤ 5, 6, 7, 8 or ≥ 9 hours per day), and educational attainment (attended school up to 12 years old, 15 years old, 18 years old, or older than 18 years old).

Outcomes: Mortality from Major Cardiovascular Diseases
------------------------------------------------------

Mortality surveillance was conducted systematically by checking death certificates, all of which were forwarded to their respective public health centers. Mortality data were then centralized at the Ministry of Health and Welfare, and the underlying causes of death were coded for the National Vital Statistics according to the International Classification of Diseases. Death registration is required by the Family Registration Law in Japan. Deaths from major CVD were defined by the International Classification of Diseases (ICD)-10 codes as follows: total CVD as I00 to I99; CHD as I20 to I25.9; heart failure as I50 to I50.9; cardiac arrhythmia as I40 to I40.9; total stroke as I60 to I60.9; ischemic stroke as I63 to I63.9 or I69.3; hemorrhagic stroke as I60 to I62.9 or I69 to I69.2; and aortic aneurysm or dissection as I71 to I71.9.

Statistical Analysis
--------------------

The person-years of follow-up for each participant were calculated from the baseline in 1988 to 1990 to the first endpoint: death, moving from the community, or the end of follow-up of 2009, except for four areas in 1999, four areas in 2003 and two areas in 2008 where follow-up had been terminated. Participants were divided into three categories ("Seldom," "Sometimes," or "Often") or two categories ("Seldom or sometimes" or "Often") according to their answers about eczema frequency, because it appears to be difficult for participants to distinguish "Seldom" and "Sometimes." Age, sex-adjusted mean values and prevalence of selected CVD risk factors were calculated according to eczema frequency. We tested the proportional hazards assumption in Cox regression using risk factors by time interactions and found it was not violated. Using Cox proportional hazard models, we calculated the hazard ratios (HRs) and their 95% confidence intervals (CIs) for mortality outcomes after adjustment for age, sex, and other CVD risk factors.

We also performed sex or age (40 to 59 vs. 60 to 79 years old)-specific analysis and tested multiplicative interactions between the eczema frequency and sex or age in relation to CVD mortality risk for sensitivity analyses. We tested interactions between sex or age and eczema frequency in relation to CVD mortality risk by adding multiplicative interaction terms in a multivariable for sensitivity analyses.

SAS Version 9.3 software (SAS Institute Inc., Cary, NC) was used for statistical analysis. All statistical tests were two-tailed and *P* values of \< 0.05 were considered significant.

Results
=======

Baseline Characteristics According to Self-Reported Frequency of Eczema
-----------------------------------------------------------------------

As shown in **[Table 1](#T1){ref-type="table"}**, compared to individuals who "seldom" or "sometimes" had eczema, those who "often" had it tended to have higher level of body mass index, histories of hypertension and diabetes, and high perceived mental stress, to be current drinkers, and to walk for more than five hours per week.

###### Age-, Sex-Adjusted Baseline Characteristics According to the Frequency of Eczema

                                             Frequency of Eczema                             
  ------------------------------------------ --------------------- -------- ------- -------- -------
  No. at risk                                64 490                15 240   5 369   79 730   5 369
      Age, years                             57.0                  56.5     57.1    56.9     57.0 
      Men, %                                 41.9                  41.0     41.4    41.7     41.4 
      Body mass index, kg/m^2^               22.8                  22.8     23.0    22.8     23.0 
      History of hypertension, %             21.4                  21.3     23.6    21.4     23.6 
      History of diabetes, %                 4.7                   5.8      7.3     4.9      7.3 
      Current drinker, %                     40.2                  41.3     41.4    40.4     41.4 
      Current smoker, %                      26.6                  26.2     26.9    26.5     26.9 
      High perceived mental stress, %        19.6                  25.3     31.4    20.7     31.4 
      Walking ≥ 5 hour/week, %               51.5                  48.6     47.9    50.9     47.9 
      Sport participation ≥ 5 hour/week, %   5.6                   6.0      5.2     5.7      5.2 
      Educated over 18 years old, %          12.9                  15.6     15.3    13.5     15.3 
      Sleep duration, hours/day              7.3                   7.2      7.2     7.3      7.2 

Association of Self-Reported Frequency of Eczema with Mortality from Several Major Cardiovascular Diseases
----------------------------------------------------------------------------------------------------------

There were 5,628 CVD deaths during the 6,389,818 person-years of follow-up. As shown in **[Table 2](#T2){ref-type="table"}**, 1,174 deaths resulted from CHD, 979 from heart failure, 366 from cardiac arrhythmia, 2,454 from total stroke, 1,357 from ischemic stroke, 1,013 from hemorrhagic stroke, and 201 from aortic aneurysm or dissection (**[Table 2](#T2){ref-type="table"}**). The age-, sex-adjusted model showed that, compared to individuals "seldom" having eczema, those "sometimes" or "often" having it had decreased or increased risk of mortality from CHD, respectively. Those "often" having eczema had an increased risk of mortality from CHD, than individuals who "seldom or sometimes" had it. Further adjustment for other CVD risk factors did not substantially change those associations; individuals who "sometimes" or "often" had eczema had 0.82 (95%CI: 0.69--0.97) or 1.26 (95%CI: 1.01--1.56) times the risk of mortality from CHD, compared to those who "seldom" did, respectively. Individuals who "often" had 1.30 (95%CI: 1.05--1.61) times the risk of mortality from CHD, compared with those who "seldom or sometimes" did it. There was no association of eczema with mortality from other CVD.

###### Hazard Ratios and 95% Confidence Intervals of Cardiovascular Mortality According to the Frequency of Eczema

                                                                         Frequency of Eczema                                                       
  ---------------------------------------------------------------------- --------------------- ------------------- ------------------- ----------- -------------------
  No. at risk                                                            64 490                15 240              5 369               79 730      5 369
  Person-years                                                           1 064 049             242 291             83 478              1 306 340   83 478
        Total cardiovascular disease, cases.                             4431                  845                 352                 5276        352
              Age-, sex-adjusted HR (95% CI)                             1                     0.94 (0.87--1.01)   1.10 (0.99--1.23)   1           1.11 (1.00--1.24)
              Multivariable[\*](#tf1){ref-type="table-fn"} HR (95% CI)   1                     0.95 (0.88--1.02)   1.05 (0.95--1.18)   1           1.06 (0.95--1.19)
        Coronary heart disease, cases                                    925                   158                 91                  1083        91
              Age-, sex-adjusted HR (95% CI)                             1                     0.84 (0.71--0.99)   1.35 (1.09--1.68)   1           1.39 (1.12--1.72)
              Multivariable[\*](#tf1){ref-type="table-fn"} HR (95% CI)   1                     0.82 (0.69--0.97)   1.26 (1.01--1.56)   1           1.30 (1.05--1.61)
        Heart failure, cases                                             758                   159                 62                  917         62
              Age-, sex-adjusted HR (95% CI)                             1                     1.05 (0.89--1.25)   1.15 (0.89--1.49)   1           1.14 (0.88--1.48)
              Multivariable[\*](#tf1){ref-type="table-fn"} HR (95% CI)   1                     1.07 (0.90--1.27)   1.12 (0.86--1.45)   1           1.11 (0.85--1.43)
        Cardiac arrhythmia, cases                                        285                   58                  23                  343         23
              Age-, sex-adjusted HR (95% CI)                             1                     1.02 (0.77--1.35)   1.16 (0.76--1.77)   1           1.15 (0.76--1.76)
              Multivariable[\*](#tf1){ref-type="table-fn"} HR (95% CI)   1                     1.01 (0.76--1.34)   1.13 (0.73--1.72)   1           1.12 (0.74--1.72)
        Total stroke, cases                                              1937                  374                 143                 2311        143
              Age-, sex-adjusted HR (95% CI)                             1                     0.95 (0.85--1.06)   1.02 (0.86--1.21)   1           1.03 (0.87--1.22)
              Multivariable[\*](#tf1){ref-type="table-fn"} HR (95% CI)   1                     0.97 (0.87--1.08)   0.98 (0.83--1.16)   1           0.98 (0.83--1.17)
        Ischemic stroke, cases                                           1081                  199                 77                  1280        77
              Age-, sex-adjusted HR (95% CI)                             1                     0.93 (0.80--1.08)   1.00 (0.79--1.26)   1           1.01 (0.80--1.27)
              Multivariable[\*](#tf1){ref-type="table-fn"} HR (95% CI)   1                     0.97 (0.84--1.13)   0.95 (0.76--1.20)   1           0.96 (0.76--1.21)
        Hemorrhagic stroke, cases                                        792                   159                 62                  951         62
              Age-, sex-adjusted HR (95% CI)                             1                     0.95 (0.80--1.13)   1.06 (0.82--1.37)   1           1.07 (0.82--1.38)
              Multivariable[\*](#tf1){ref-type="table-fn"} HR (95% CI)   1                     0.95 (0.80--1.13)   1.03 (0.80--1.34)   1           1.04 (0.81--1.35)
        Aortic aneurysm or dissection, cases                             164                   25                  12                  189         12
              Age-, sex-adjusted HR (95% CI)                             1                     0.74 (0.48--1.12)   1.01 (0.56--1.81)   1           1.06 (0.59--1.89)
              Multivariable[\*](#tf1){ref-type="table-fn"} HR (95% CI)   1                     0.76 (0.50--1.17)   0.97 (0.54--1.75)   1           1.01 (0.56--1.82)

HR, hazard ratio; CI, confidence interval.

Adjusted for age, sex, body mass index, history of hypertension, history of diabetes, alcohol intake, smoking status, perceived mental stress, daily walking time, participation in sports, sleep duration, and educational attainment.

Sensitivity Analysis
--------------------

We reran models for CHD after stratifying participants by sex or age (40 to 59 vs. 60 to 79 years old), and obtained similar results to main results (*p* values for interactions by sex or age were 0.99 in three categories and 0.97 in two categories, or 0.34 in three categories and 0.24 in two categories, respectively) (**[Table 3](#T3){ref-type="table"}**).

###### Multivariable Hazard Ratios and 95% Confidence Intervals of Mortality from Coronary Heart Disease According to the Frequency of Eczema

                                                                   Frequency of Eczema                                                         
  ---------------------------------------------------------------- --------------------- ------------------- ------------------- ------------- -------------------
  Coronary heart disease                                                                                                                       
  Men                                                                                                                                          
  Person-years/cases.                                              435 433/523           97 741/92           33 909/56           533 173/615   33 909/56
        Multivariable[\*](#tf2){ref-type="table-fn"} HR (95% CI)   1                     0.81 (0.64--1.01)   1.28 (0.97--1.68)   1             1.32 (1.00--1.74)
  Women                                                                                                                                        
  Person-years/cases                                               628 617/402           144 550/66          49 569/35           773 167/468   49 569/35
        Multivariable[\*](#tf2){ref-type="table-fn"} HR (95% CI)   1                     0.85 (0.65--1.11)   1.28 (0.90--1.81)   1             1.31 (0.93--1.85)
  40--59 years old                                                                                                                             
  Person-years/cases                                               660 907/205           157 620/33          54 278/27           818 527/238   54 278/27
        Multivariable[\*](#tf2){ref-type="table-fn"} HR (95% CI)   1                     0.68 (0.47--0.99)   1.58 (1.06--2.38)   1             1.69 (1.13--2.52)
  60--79 years old                                                                                                                             
  Person-years/cases                                               403 142/720 1         84 671/125          29 199/64           487 813/845   29 199/64
        Multivariable[\*](#tf2){ref-type="table-fn"} HR (95% CI)   1                     0.84 (0.69--1.02)   1.20 (0.93--1.56)   1             1.24 (0.96--1.60)

HR, hazard ratio; CI, confidence interval.

Adjusted for age, sex, body mass index, history of hypertension, history of diabetes, alcohol intake, smoking status, perceived mental stress, daily walking time, participation in sport, sleep duration, and educational attainment.

Discussion
==========

In this prospective cohort study of Japanese men and women, we investigated the associations of eczema frequency with mortality from several major CVDs, and found that individuals who often had eczema had an increased risk of mortality from CHD, but not from stroke, heart failure, cardiac arrhythmia, stroke, either aortic aneurysm or dissection, compared to those who seldom or sometimes did. The association did not differ between men and women or younger and older people. To the best of our knowledge, this is the first study to find an association between eczema and mortality from CHD in a Japanese general population.

Previous reports about the association of eczemarelated diseases with CVD are mainly from Western countries. A previous meta-analysis by Miller et al. reported that psoriasis was associated with increased risk of CHD (odds ratio \[OR\] 1.5; 95% CI 1.2--1.9), but not stroke (OR 1.1; 95% CI 0.9--1.3), and in a subgroup analysis, such a significant association was seen only in hospital-based studies (OR 1.7; 95% CI 1.2--2.5) but not in population-based studies (OR 1.3 95% CI 1.0--1.8)^[@bib16])^. Standl *et al.* reported that in AOK (Allgemaine Ortskrankenkasse) PLUS cohort from a statutory German health insurer data, atopic dermatitis was marginally associated with an increased risk of angina pectoris (risk ratio \[RR\] 1.17; 95%CI 1.12--1.23) and peripheral arterial disease (RR 1.15; 95%CI 1.11--1.19), but not myocardial infarction (RR 1.05; 95%CI 0.99--1.12) or stroke (RR 1.02; 95%CI 0.98--1.19). They concluded that relevant associations of atopic dermatitis with CVD could not be confirmed^[@bib17])^. There are also some reports from Asian countries. Psoriasis Vulgaris was associated with CHD in a Japanese retrospective hospital-based study (OR: 1.27; 95%CI 1.01--1.58)^[@bib19])^. A Chinese case-control study showed that the prevalence of myocardial infarction was 1.72 (95%CI 1.29--2.30) and 2.01 (95%CI 1.45--2.79) times higher in patients with mild and severe psoriasis, respectively, than those in controls^[@bib20])^. In a Taiwanese longitudinal study, patients with mild, moderate and severe atopic dermatitis had 1.20 (95%CI 0.99--1.45), 1.64 (95%CI 1.23--2.19), 1.71 (95%CI 1.15--2.56) times higher risk of ischemic stroke, respectively, than those without atopic dermatitis in a dose-response manner^[@bib21])^.

In our study, frequent eczema was associated with increased risk of mortality from CHD but not from the other CVD. Inflammation may be associated with increased risk of stroke, another major atherosclerotic disease, as well as CHD, but its contribution to stroke risk was smaller than CHD risk^[@bib22]--[@bib24])^. In addition, the number of deaths from heart failure, cardiac arrhythmia and aortic aneurysm or dissection were fewer than those from CHD. Thus, we might have been able to identify only the association with risk of mortality from CHD.

Some skin diseases causing eczema may be associated with systemic inflammation. For example, in psoriasis, Th-1, Th-17 and Th-22 induce inflammation through deregulating interferon production and tumor necrosis factor^[@bib25])^. In atopic dermatitis, there is a perivascular infiltration of immune factors or cells such as immunoglobulin E, T lymphocytes, and mast cells. C-reactant protein, thymus and activation-regulated chemokine, and immunoglobulin E, known as inflammatory markers, are elevated in patients with atopic eczema^[@bib13],\ [@bib26])^. Those inflammatory processes might have accelerated atherosclerosis^[@bib27]--[@bib33])^, leading to increased risk of mortality from CHD.

In the present study, individuals who reported having eczema "sometimes" had a decreased risk of mortality from CHD, compared to those "seldom" having eczema. One reason for this finding may be chance, but another may be a misclassification between those two groups. Considering that possibility, we also compared participants who reported having eczema "seldom or sometimes" to those having eczema "often," and found that individuals who "often" had eczema had an increased risk of mortality from CHD compared to those who "seldom or sometimes" had it.

This study\'s strengths include its prospective design and a long follow-up duration. In addition, we used several major CVDs as outcomes, and found that the high frequency of eczema was associated with risk of CHD, but not other CVD outcomes.

We should acknowledge several limitations. Firstly, eczema was self-reported and was defined without any precise medical examination by dermatologists. In addition, our questionnaire about eczema frequency has not been validated. Thus, we cannot rule out the possibility of misclassification for exposure. Secondly, we did not include information on using the adrenal cortex hormone as a potential confounding factor. The adrenal cortex hormone is often used as an eczema treatment, and the adrenal cortex hormone is also known as a risk factor for cardiovascular disease^[@bib34])^. Thirdly, we used mortality data, but not incident data, for endpoints. Although the death certificates diagnoses\' validity was confirmed^[@bib35],\ [@bib36])^, outcome misclassification is still possible. Fourthly, we assessed the association between eczema and CVD risk without considering blood lipids because data on blood concentrations of lipids was available for the subsample, but not for all participants. However, a previous study of US adults reported weak associations of eczema with history of high total cholesterol, told by a doctor or other health professionals^[@bib37])^. When we analyzed the subsample of the participants who had serum total cholesterol level data (*n* = 26,222), we found no HR alterations. The HRs (95%CIs) were 1.52 (1.01--2.28) in age- and sex-adjusted model and 1.51 (1.01--2.26) in age-, sex- and total cholesterol-adjusted model. The corresponding multivariable HRs (CIs) were 1.38 (0.92--2.08) and 1.38 (0.91--2.08). Thus, total cholesterol was unlikely to confound the association in the present study.

In conclusion, self-reported eczema was associated with increased risk of mortality from CHD, but not other major CVD such as stroke in a Japanese general population.
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